Work

493TiP A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.621

Authors: J.S. de Bono, S. Lord, C. Yap, E.K. Rowinsky, N.A. Gandhi, D. Thakkar, P.J. Ingram, N. Padmanabhan, K. Chandran, A. Paschalis, L. McGuigan, P. Neal, D. Paisley, H.S. Walter, F. Kelly, J. Craigan, N.B. Westwood, G. Halbert, J.D. Boyd-Kirkup, S.E.R. Halford

Institutions: Institute of Cancer Research, University of Oxford, Temasek Life Sciences Laboratory, Royal Marsden Hospital, Cancer Research UK

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4296007368

FWCI:

Cites:

Cited by:

Related to: 10